| Gene Name |
Pubmed ID |
Classification |
Sample Location |
Remark |
| CDKN2A | 15771902 | Upregulation | - | CDKN2A protoncogene showed a 10.4 fold higher increase expression in malignant cervical squamous cells |
| CDKN2A | 16353136 | Upregulation | Department of Obstercis and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong. | CDKN2A showed a 6.65 fold increase expression and expressed higher in cervical CIN (75%) and in squamous cell carcinoma than normal or inflamed cervices. |
| CDKN2A | 15073118 | Overexpression | Umea University Hospital, Sweden | The overexpression of p14ARF or CDKN2A is found to be significantly higher in CIN (75%) and in SCC (75%) than in normal or inflammation of the cervix (12.5%; P<0.01, P<0.05 respectively). |
| CDKN2A | 17596760 | - | Perola Byington Hospital, Sao Paulo, Brazil | This gene suppress the activity of CDK4 and CDK6 , which is an essential function in oncology. |
| CDKN2A | 17306351 | Overexpression | Clinic of Obstetrics and Gynaecology at the Medical University of Vienna, Austria. | Overexpression of CDKN2A proved to be a reliable marker for the identification of cervical dysplasia. It is found to be 10.40 fold level increase in HR-HPV(-) squamous cervical cells. |
| CDKN2A | 14760078 | Methylation | Department of Obsterics and Gynecology, Innsbruck University Hospital. | Aberrant methylation of CpG island within the promoter regions. |
| CDKN2A | 11448914 | Methylation | Samsung Cheil Hospital, Seoul, Korea | Aberrant methylation of CpG island within the promoter regions in asscoiation with the loss of protein expression in cancer cells. |
| CDKN2A | 11297252 | Methylation | Parkland Health and Hospital System, Dallas, Texas. | p16 gene is more methylated in high-grade lesions(CIN2 and CIN3; P=0.001 and P=0.004 respectively, as well as in cervical tumors than in the nondysplasia/low-grade CIN group. |
| CDKN2A | 12702579 | Methylation | Anatomical Pathology Department of the City of Hope National Medical Center. | Aberrant methylation of CpG island within the promoter regions has been observed in 25-50% of the tumors has been observed in the 25-50% of the tumors. |
| CDKN2A | 16331610 | Methylation | Gynecologic Oncology Division of Seoul National University Hospital | This gene showed an intermediate methylation (15-40%). |
| CDKN2A | 16028838 | - | Department of Pathology, Farhet Hached University Hospital, Sousse, Tunisia. | A statistical significant association between p16INK4a overexpression, lesion grade and high risk HPV infection (p<0.0001). |
| CDKN2A | 17192788 | - | Department of pathology of the Umass Memorial Medical Center | p16INK4A is overexpressed inn all cases of adenocarcinoma in situ with the sensitivity of 100%. |
| CDKN2A | 20400236 | - | Department of Pathology, Farhet Hached University Hospital, Sousse, Tunisia. | A statistical significant association between p16INK4a overexpression, lesion grade and high risk HPV infection (p<0.0001). p16INK4A is uniformly observed in both the nucleus and the cytoplasm of all CIN2 and 3, as well as those of invasive SCC and adenocarcinoma. |
| CDKN2A | 20186007 | Methylation | Cervical Pathology Unit of the Institute of Gynecology. | Methylation of p16INK4A gene constituted an occurrence that is early but independent of the presence of HPV DNA. |
| CDKN2A | 15589597 | Methylation | Department of Obstertics and Gynecology, Seoul national University Hospital. | Frequency of methylation of p16 is found to be 19.5%. |
| CDKN2A | 18813814 | Upregulation | Department of Obsterics and Gynaecology of the University Hospital of Heraklion, Crete | This gene is found to be upregulated 86%,82% and 77% in cervical cancer,HSIL and LSIL cases. |
| CDKN2A | 20112504 | Methylation | Oncology Center of Casablanca Morocco | Hypermethylation of 5' CpG island of the p16INK4a was found to be 59.1%; 13 of 22 cervical sample. |
| CDKN2A | 15785933 | Methylation | Department of pathology, Anam Hospital of Korea University | None of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma |
| CDKN2A | 16803511 | Methylation | Busan Paik Hospital, Inje University, Busan, South Korea. | The frequencies of promoter methylation of p16, DAPK, CDH1, and TIMP-3 in cervical cancer were 57%, 44.9%, 52.6%, and 9%, respectively |
| CDKN2A | 16928264 | Methylation | - | Incidence of hypermethylation for DAPK, MGMT, p16 and PTEN in cervical cancer was 56.7%, 25.2%, 16.5% and 15.7% respectively |
| CDKN2A | 15099958 | Methylation | Queen Mary Hospital, Hong Kong. | Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA, and in 40%, 10%, and 7.5% of cases of patients' plasma DNA |
| CDKN2A | 12773202 | Methylation | - | high frequency of promoter methylation in CDH1, DAPK, RARB, and HIC1 genes |
| CDKN2A | 16778587 | Methylation | - | Analysis of MSP showed that 20 of the 38 CIN patients (52.6%) revealed hypermethylation in at least 1 primer set of the p16INK4a promoter |
| CDKN2A | 15713962 | Methylation | - | hypermethylated in 74% of 19 ICC samples |
| CDKN2A | 17359536 | Upregulation | - | Cytoplasmic accumulation of p16inka4 is a feature of cervical carcinomas. Upregulation of expression of P16 in HPV-positive cervical carcinomas has been reported. |